CN110382539B - 用于cd16a定向的nk细胞结合的串联双抗体 - Google Patents

用于cd16a定向的nk细胞结合的串联双抗体 Download PDF

Info

Publication number
CN110382539B
CN110382539B CN201880014655.0A CN201880014655A CN110382539B CN 110382539 B CN110382539 B CN 110382539B CN 201880014655 A CN201880014655 A CN 201880014655A CN 110382539 B CN110382539 B CN 110382539B
Authority
CN
China
Prior art keywords
cd16a
amino acid
cells
linker
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880014655.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN110382539A (zh
Inventor
索斯藤·罗斯
伊维卡·法斯克
克里斯蒂娜·埃尔旺格
迈克尔·维柴尔
乌维·罗伊施
斯特凡·奈克马斯
埃里希·拉伊科维奇
马丁·特里德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of CN110382539A publication Critical patent/CN110382539A/zh
Application granted granted Critical
Publication of CN110382539B publication Critical patent/CN110382539B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880014655.0A 2017-02-28 2018-02-28 用于cd16a定向的nk细胞结合的串联双抗体 Active CN110382539B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17158566 2017-02-28
EP17158566.4 2017-02-28
EP17174407 2017-06-02
EP17174407.1 2017-06-02
PCT/EP2018/054989 WO2018158349A1 (en) 2017-02-28 2018-02-28 Tandem diabody for cd16a-directed nk-cell engagement

Publications (2)

Publication Number Publication Date
CN110382539A CN110382539A (zh) 2019-10-25
CN110382539B true CN110382539B (zh) 2023-08-08

Family

ID=61569251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880014655.0A Active CN110382539B (zh) 2017-02-28 2018-02-28 用于cd16a定向的nk细胞结合的串联双抗体

Country Status (8)

Country Link
US (2) US11180558B2 (https=)
EP (1) EP3589655B1 (https=)
JP (1) JP7115758B2 (https=)
CN (1) CN110382539B (https=)
AU (1) AU2018228719B2 (https=)
CA (1) CA3051062C (https=)
DK (1) DK3589655T3 (https=)
WO (1) WO2018158349A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
CN116368154A (zh) * 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
CR20230229A (es) * 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
JP2024503933A (ja) * 2021-01-27 2024-01-29 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
WO2023274183A1 (zh) * 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
IL312515A (en) * 2021-11-03 2024-07-01 Affimed Gmbh Bispecific cd16a binders
US20260070986A1 (en) * 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
CN114262382B (zh) * 2021-12-20 2023-09-19 上海恩凯细胞技术有限公司 双特异性抗体及其应用
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN115960234B (zh) * 2022-10-27 2023-12-29 合肥天港免疫药物有限公司 抗cd16a的抗体及其应用
EP4640700A1 (en) 2022-12-19 2025-10-29 Harbour Biomed (Shanghai) Co., Ltd "kappa/lambda" fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN121591895A (zh) * 2024-08-23 2026-03-03 安升（上海）医药科技有限公司 一种抗CD16a的单域抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583625A (zh) * 2005-05-26 2009-11-18 阿菲姆德农业医药公司 抗-cd16结合分子
CN101821288A (zh) * 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
CN103687879A (zh) * 2011-07-22 2014-03-26 阿菲姆德农业医药公司 多价抗原结合fv分子
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
WO2002066516A2 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
ES2283368T3 (es) * 2001-11-14 2007-11-01 Affimed Therapeutics Ag Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
EP2361936B1 (en) * 2010-02-25 2016-04-20 Affimed GmbH Antigen-binding molecule and uses thereof
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
LT3030581T (lt) 2013-08-07 2021-05-25 Affimed Gmbh Antikūno surišimo vietos specifiškos egfrviii
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
LT3292153T (lt) * 2015-05-04 2019-11-11 Affimed Gmbh Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583625A (zh) * 2005-05-26 2009-11-18 阿菲姆德农业医药公司 抗-cd16结合分子
CN101821288A (zh) * 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
CN103687879A (zh) * 2011-07-22 2014-03-26 阿菲姆德农业医药公司 多价抗原结合fv分子
CN105367660A (zh) * 2015-12-22 2016-03-02 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Also Published As

Publication number Publication date
AU2018228719B2 (en) 2023-03-30
CN110382539A (zh) 2019-10-25
AU2018228719A1 (en) 2019-08-08
US11180558B2 (en) 2021-11-23
CA3051062A1 (en) 2018-09-07
DK3589655T3 (da) 2022-11-28
WO2018158349A1 (en) 2018-09-07
JP2020510659A (ja) 2020-04-09
US20190345249A1 (en) 2019-11-14
EP3589655B1 (en) 2022-10-26
US20220041717A1 (en) 2022-02-10
EP3589655A1 (en) 2020-01-08
JP7115758B2 (ja) 2022-08-09
CA3051062C (en) 2023-09-26
US12264198B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
US20170304437A1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
JP2020529832A (ja) ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
JP2019533444A (ja) ＩＬ−１５／ＩＬ−１５ＲアルファＦｃ融合タンパク質およびＰＤ−１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
WO2023036270A1 (zh) 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
US20240174768A1 (en) Bispecific antibodies enhancing cell mediated immune responses
JP2025540657A (ja) 抗ｃｄ３抗体
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
HK40066389A (zh) 自然杀伤细胞接合抗体融合构建体
HK40066055A (zh) 自然杀伤细胞接合抗体融合构建体
JP2024522078A (ja) 抗ｇｐｃ３及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40034204A (en) Nk cell engaging antibody fusion constructs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant